HLS Net Income from 2010 to 2026

HLS Stock  CAD 4.65  0.05  1.06%   
HLS Therapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to about -16.8 M this year. During the period from 2010 to 2026, HLS Therapeutics Net Loss quarterly data regression pattern had sample variance of 218.9 T and median of (13,117,000). View All Fundamentals
 
Net Loss  
First Reported
1997-03-31
Previous Quarter
-2.7 M
Current Value
-3.9 M
Quarterly Volatility
3.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

Latest HLS Therapeutics' Net Income Growth Pattern

Below is the plot of the Net Income of HLS Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in HLS Therapeutics financial statement analysis. It represents the amount of money remaining after all of HLS Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is HLS Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (19.66 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

HLS Net Income Regression Statistics

Arithmetic Mean(7,564,014)
Geometric Mean11,101,239
Coefficient Of Variation(195.58)
Mean Deviation12,942,165
Median(13,117,000)
Standard Deviation14,793,678
Sample Variance218.9T
Range44.4M
R-Value(0.86)
Mean Square Error61.9T
R-Squared0.73
Significance0.000011
Slope(2,511,237)
Total Sum of Squares3501.6T

HLS Net Income History

2026-16.8 M
2025-17.7 M
2024-19.7 M
2023-27.5 M
2022-23.6 M
2021-13.1 M
2020-15.3 M

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as Net Income, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-17.7 M-16.8 M
Net Loss-17.7 M-18.6 M
Net Loss-17.7 M-18.6 M
Net Loss(0.71)(0.67)
Net Income Per E B T 1.45  1.36 

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.